Ces Urol 2014, 18(2):85-93 | DOI: 10.48095/cccu2014020

Intravesical therapy of urinary bladder tumours

Viktor Soukup, Otakar Čapoun, Michael Pešl, Zuzana Feherová, Tomáš Hanuš

Urologická klinika 1. LF UK a VFN, Praha

According to current guidelines, intravesical treatment should be offered to every patient with non-muscle invasive bladder cancer. The type of intravesical therapy should be based on the risk of recurrence and progression. In patients with low risk Ta tumours, a single intravesical instillation, immediately following resection, is recommended. A full course of intravesical chemotherapy or BCG instillation is recommended in all remaining risk groups. In patients with intermediate-risk tumours, one immediate post-resection administration of intravescial chemotherapy should be followed by one year of full course BCG treatment, or additional intravesical chemotherapy for a maximum of one year. In patients with high--risk tumours, full-dose intravesical BCG for 1-3 years should be administered. In tumours with a high risk of progression, immediate radical cystectomy should be considered. In BCG refractory tumours, a radical cystectomy should be performed as well.

Keywords: urinary bladder tumours, adjuvant intravesical therapy, intravesical chemotherapy, BCG, recurrence, progression

Received: December 19, 2013; Accepted: January 24, 2014; Published: March 1, 2014